Oramed Pharmaceuticals Inc.

321 articles about Oramed Pharmaceuticals Inc.

• Oramed Letter to Shareholders - July 07, 2022

  7/7/2022

  Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.

• Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

  6/1/2022

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters , MD, to its Scientific Advisory Board.

• Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

  5/24/2022

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes."  

• Oramed to Present at H.C. Wainwright Global Investment Conference in May 2022

  5/18/2022

  Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that Chief Executive Officer Nadav Kidron will present an in-person company overview at the H.C. Wainwright Global Investment Conference, on May 25, 2022 in Miami, Florida.

• Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

  5/3/2022

  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced it has completed patient enrollment for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D), surpassing its target of 675 patients with 710 patients enrolled. 

• Oramed Granted NASH Patent in Europe

  4/5/2022

  Oramed Pharmaceuticals Inc. today announced that the European Patent Office has granted the Company the patent titled "Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof."

• Oramed Appoints Yadin Rozov to its Board of Directors

  4/4/2022

  Oramed Pharmaceuticals Inc. today announced the appointment of Yadin Rozov to its Board of Directors effective April 1, 2022.

• Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

  3/29/2022

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), today announced results from a diabetes market survey commissioned by Oramed from IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.

• Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

  3/22/2022

  Oramed Pharmaceuticals Inc. today announced that it will host a webinar with Key Opinion Leaders (KOLs) on the need for oral insulin in type 2 diabetes on Wednesday, March 30, 2022, at 12:00 p.m. Eastern Time.

• 

  Clinical Catch-Up: New SMA and Alzheimer's Data

  3/21/2022

  It was a busy week for clinical trial announcements. Here's a look.

• Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial

  3/16/2022

  Oramed Pharmaceuticals Inc. today announced it has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH).

• Oramed to Present at Barclays Global Healthcare Conference

  3/10/2022

  Oramed Pharmaceuticals Inc. announced today that Chief Executive Officer Nadav Kidron will present a live company overview at the Barclays Global Healthcare Conference, to be held in Miami, Florida.

• Oramed Issues Annual Message to Shareholders

  1/12/2022

  Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.

• Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

  1/5/2022

  Oramed Pharmaceuticals Inc. announced the European Patent Office has granted the Company a patent titled "Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same."

• MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

  12/29/2021

  MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), announced today that its investment company Oravax Medical Inc. (“Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (“Oramed”), has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company.

• Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

  12/29/2021

  Oramed Pharmaceuticals Inc. announced that its subsidiary, Oravax Medical, has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to pre-purchase Oravax's oral COVID-19 vaccine, currently in development.

• Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

  12/14/2021

  Oravax's oral vaccine targets three surface proteins, making it potentially more effective against current and future variants.

• Oramed Pharmaceuticals Appoints Chief Legal Officer

  12/8/2021

  Oramed Pharmaceuticals Inc. today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022 .

• Oramed to Join MSCI USA Small Cap Index

  11/24/2021

  Oramed Pharmaceuticals Inc. announced today that its common stock will be added to the MSCI USA Small Cap Index effective Tuesday, November 30th at the close of market.

• Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

  11/23/2021

  Oramed Pharmaceuticals Inc. announced today that it has enrolled and randomized over 75% of the 675 patients planned for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).